Research & Development

27 Aug 2019
- Drug Discovery
- Research & Development
ADC Therapeutics and Freenome enter biomarker development collaboration

By PBR Staff Writer

ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of antibody drug conjugates (ADCs), and Freenome, a biotechnology company that has pioneered the most comprehensive multiomics platform for early cancer detection through a routine blood draw, announced that they have entered a biomarker development collaboration in which ADC Therapeutics will use Freenome’s platform to identify patients who are most likely to respond to treatment with ADCT-402 (loncastuximab tesirine).
26 Aug 2019
Drug Discovery
Research & Development
Cantargia, BioWa extend ongoing collaboration around POTELLIGENT technology

By PBR Staff Writer

Cantargia and BioWa have signed an extension of the licence agreement around the BioWa proprietary POTELLIGENT technology for production of Cantargia’s antibody drug candidate CAN04, which gives Cantargia broader rights to use the technology.
26 Aug 2019
Drug Discovery
Research & Development
Gilead, Galapagos finalise £4.1bn research and development deal

By PBR Staff Writer

Gilead Sciences has finalised its 10-year global research and development deal, worth up to $5.05bn (£4.11bn), with Belgium-based Galapagos following regulatory clearances.
23 Aug 2019
Drug Discovery
Research & Development
Finch raises £43m to advance microbiome-based therapies for recurrent CDI, Autism and other disease areas

By PBR Staff Writer

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, announced today the completion of a $53m (£43.38m) Series C financing.
22 Aug 2019
Drug Discovery
Research & Development
Oncorus raises £65.5m funding to advance oncolytic virus therapies

By PBR Staff Writer

US-based Oncorus has raised $79.5m (£65.56m) in a Series B financing round co-led by Cowen Healthcare Investments and Perceptive Advisors.
21 Aug 2019
Drug Discovery
Research & Development
Graybug Vision secures £66m to advance retina and glaucoma clinical programs

By PBR Staff Writer

Graybug Vision, a clinical stage pharmaceutical company developing potentially transformative long-acting therapies for ocular diseases including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and primary open angle glaucoma (POAG), today announced the securing of an $80 million (£66m) Series C financing.
20 Aug 2019
Drug Discovery
Research & Development
Angel-funded Siamab completes £166m exit with large commercial-stage biopharma

By PBR Staff Writer

Siamab Therapeutics, a biopharmaceutical company developing novel glycan-targeted cancer therapeutics, has entered into a strategic agreement valued at up to $202m (£166m) with an undisclosed, large commercial-stage biopharmaceutical company under which such company will develop and commercialise antibody-based products targeting a tumor-associated carbohydrate antigen (TACA) identified by Siamab’s proprietary TACA discovery platform.
20 Aug 2019
Drug Discovery
Research & Development
Mexico-based Sanfer gets £413m investment from CDPQ

By PBR Staff Writer

Caisse de dépôt et placement du Québec (CDPQ), a Canadian long-term institutional investor, has agreed to make a minority investment of $500m (£413.8m) in Mexican pharmaceutical company Sanfer.
19 Aug 2019
Drug Discovery
Research & Development
Xynomic Research Institute successfully designs series of potent RET kinase inhibitors

By PBR Staff Writer

Xynomic Pharmaceuticals Holdings, a clinical stage US-China oncology drug development company, announced that Xynomic Research Institute (XRI) has successfully designed a series of potent RET kinase inhibitors by computer-assisted drug design.
16 Aug 2019
Drug Discovery
Research & Development
GeneCentric Therapeutics acquires Select ImmunoGenomics

By PBR Staff Writer

GeneCentric Therapeutics announced that it has acquired Select ImmunoGenomics, LLC, a Chapel Hill, NC-based provider of advanced immunogenomic, data analysis and biomarker development services to support the development of immuno-oncology drugs.

Drug Discovery

Research & Development

EverSea Medicines to acquire Hasten Biopharmaceuticals

Jeito Capital secures over $1.2bn for new biopharma investments

Clinical Trials

Patient Enrollment

US FDA approves Avacta Group’s IND application for AVA6000

AM-Pharma enrols first patients in Covid-19 phase III trial

Regulation

Drug Filing

Viatris files applications in Japan for approval of Effexor to treat GAD

Scholar Rock submits application of SMA therapy to FDA

Production & Sales

Manufacturing

ENCell and Lucy Biotech forge alliance for mesenchymal stem cell therapy

Merck introduces single-use reactor to accelerate ADC manufacturing

Packaging & Supply Chain

Packaging

Gerresheimer at CPHI Frankfurt 2025

Gerresheimer

Suppliers

No data found

Research & Development

ADC Therapeutics and Freenome enter biomarker development collaboration

Cantargia, BioWa extend ongoing collaboration around POTELLIGENT technology

Gilead, Galapagos finalise £4.1bn research and development deal

Finch raises £43m to advance microbiome-based therapies for recurrent CDI, Autism and other disease areas

Oncorus raises £65.5m funding to advance oncolytic virus therapies

Graybug Vision secures £66m to advance retina and glaucoma clinical programs

Angel-funded Siamab completes £166m exit with large commercial-stage biopharma

Mexico-based Sanfer gets £413m investment from CDPQ

Xynomic Research Institute successfully designs series of potent RET kinase inhibitors

GeneCentric Therapeutics acquires Select ImmunoGenomics

Pharmaceutical Business review is using cookies

Research & Development

Patient Enrollment

Drug Filing

Manufacturing

Packaging

No data found